VYNE Therapeutics
VYNE
33 hedge funds and large institutions have $14.3M invested in VYNE Therapeutics in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 12 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
3% more funds holding
Funds holding: 32 → 33 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5.09% less ownership
Funds ownership: 54.91% → 49.82% (-5.1%)
11% less capital invested
Capital invested by funds: $16.1M → $14.3M (-$1.78M)
58% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$44.6K |
| 2 |
BlackRock
New York
|
+$42.6K |
| 3 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$34.7K |
| 4 |
PCM
Prelude Capital Management
New York
|
+$214 |
| 5 |
Barclays
London,
United Kingdom
|
+$190 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$740K |
| 2 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$270K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$90.3K |
| 4 |
AA
AlphaCentric Advisors
San Juan,
Puerto Rico
|
-$79.6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$47.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| $3.38K | – | – | – |
|
|
MLA
27
MB, Levis & Associates
Center Valley,
Pennsylvania
| $1.96K | – | – | – |
|
|
CA
28
Centerpoint Advisors
Needham,
Massachusetts
| $1K | – | – | – |
|
29
Russell Investments Group
London,
United Kingdom
| $351 | – | – | – |
|
30
JP Morgan Chase
New York
| $332 | +$2 | +1 | +0.6% |
|
|
31
Barclays
London,
United Kingdom
| $188 | +$190 | +100 | New |
|
32
Wells Fargo
San Francisco,
California
| $122 | – | – | – |
|
|
33
UBS Group
Zurich,
Switzerland
| $26 | -$47.5K | -25,044 | -100% |
|
|
ATPW
34
Ashton Thomas Private Wealth
Scottsdale,
Arizona
| – | -$37 | -19 | Closed |
|
VYNE Hedge Fund Activity: Q3 2024 in Review
33 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q3 2024, worth a combined $14.3M — down 11% from $16.1M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new VYNE positions and 1 closed out — a net gain of 1 holder — while 5 added to existing stakes and 12 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $44.6K. The largest seller was Silverarc Capital Management, cutting an estimated $740K.
- 33 institutional investors held VYNE Therapeutics (VYNE) as of Q3 2024, up from 32 in Q2 2024.
- Funds reported $14.3M of VYNE Therapeutics stock for Q3 2024, down 11% quarter-over-quarter.
- 2 funds opened new VYNE Therapeutics positions in Q3 2024 and 1 closed out, a net change of +1 holder.
- The largest VYNE Therapeutics buyer in Q3 2024 was Renaissance Technologies, an estimated $44.6K added.
- The largest VYNE Therapeutics seller in Q3 2024 was Silverarc Capital Management, an estimated $740K sold.
Based on aggregated 13F filings for Q3 2024.